Raymond James Financial Estimates TSE:MDP Q4 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Raymond James Financial dropped their Q4 2026 earnings per share estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Thursday, June 26th. Raymond James Financial analyst M. Freeman now anticipates that the company will earn $0.01 per share for the quarter, down from their prior estimate of $0.06. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James Financial also issued estimates for Medexus Pharmaceuticals’ FY2030 earnings at $2.60 EPS.

Medexus Pharmaceuticals Stock Performance

Shares of Medexus Pharmaceuticals stock opened at C$3.17 on Monday. The stock has a market capitalization of C$70.97 million, a price-to-earnings ratio of 15.16 and a beta of 1.96. The company has a fifty day moving average of C$2.88 and a 200-day moving average of C$3.00. Medexus Pharmaceuticals has a 52-week low of C$1.71 and a 52-week high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.